跳至主要内容
临床试验/NCT01890291
NCT01890291已完成不适用

Long Term Study of 'Immuncell-LC Groups' and 'Non-treatment Groups' in Patient Undergo Curative Resection (PEIT, Radiofrequency Ablation [RFA] or Operation) for Hepatocellular Carcinoma in Korea

GC Cell Corporation5 个研究点 分布在 1 个国家目标入组 162 人开始时间: 2013年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
162
试验地点
5
主要终点
To evaluate recurrence-free survival

研究概览

简要总结

To observation that long term follow-up study of 'Immuncell-LC groups' and 'Non-treatment groups' in patient undergo curative resection (PEIT, RFA or Operation) for hepatocellular carcinoma in Korea

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
20 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Prior to the test, patient is fully explained about the purpose/ contents and characteristics of the testing medication, and the patient him(her)self, the guardian or the legal representative signed on written consent.
  • Patients of participated in the(ClinicalTrials.gov Identifier:NCT00699816)clinical trial.

排除标准

  • Patient who is incongruent to this clinical trial by sub-investigator's opinion.

结局指标

主要结局

To evaluate recurrence-free survival

时间窗: up to 3 years

Radiological test should be operated by dynamic CT(using 64 cut), dynamic MRI or by angiography.

次要结局

  • To determine the response rate to evaluate overall survival and cause specific survival and changes of Alpha feto protein (AFP) figures from baseline to the last observation date.(up to 3 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验